UC Irvine Health

# Brain Cancer Clinical Trials

Chao Family Comprehensive Cancer Center
A National Cancer Institute-Designated Comprehensive Cancer Center

## CORRELATIVE

**UCI 10-10**
Collecting Brain Tumor Specimens for Glioma Vaccine (Bota)

**UCI 12-18**
Comprehensive, Coordinated Clinical, Imaging and Histological Database for the Study of Neurological Outcomes of Cancer and Cancer Treatments (Bota)

**EAF151**
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab In Patients with Recurrent Glioblastoma (Chow)

**UCI 17-13**
VIGILANT: Registry to Collect Safety/Efficacy Info of Gliadel Wafer Used in Medical Practice (Carrillo)

**BRAIN CANCER**

## SYMPTOM MANAGEMENT

**ACOSOG A221101**
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme (Carrillo)

## mets-SPECIFIC

**UCI 15-79**
Phase II Open-label randomized study of radiosurgery with or without Tumor Treating Fields (TT Fields) for 1-10 brain metastases from NSCLC (Carrillo)

**UCI 16-74**
A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Carrillo)

** opening soon



For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

UC Irvine Health

# Brain Cancer Clinical Trials

Chao Family Comprehensive Cancer Center
A National Cancer Institute-Designated Comprehensive Cancer Center

**BRAIN CANCER**

## THERAPEUTIC 1ST LINE

**UCI 16-55**
Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma (Bota)

**NRG BN001**
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma (Kong)

**NRG BN003**
Ph III Trial of observation versus irradiation for a gross totally resected grade II meningioma (Kong)

**UCI 17-115****
Phase II trial of AV-GBM-1 as an adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma (Bota)

**UCI 17-88****
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with RT and TMZ in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (Bota)

**UCI 16-56****
Ph II Study of Optune in Bevacizumab-Naïve Subjects w/ Recurrent WHO grade III Malignant Astrocytoma (Bota)

**UCI 17-35****
Ph II Trial of DSP-7888 Dosing Emulsion Combo w/ Bev vs Bev Alone for Glioblastoma (Kong)

**RTOG 3503**
Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma (Kong)

## THERAPEUTIC 2ND LINE

**ECOG-EAY131**
Molecular Analysis for Therapy Choice – MATCH (Seery)

**SWOG S1609**
Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors – DART (Bota)

**UCI 16-22**
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflomithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy (Bota)

**UCI 15-99**
**SUSPENDED**
Open-Label, Non-Randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients with Relapsed or Refractory Primary CNS Lymphoma (Bota)

**ALLIANCE A071401**
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations (Carrillo)

**UCI 13-14**
Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671 + GM-CSF + Cyclophosphamide) + Bevacizumab vs. (Placebo Injection + Placebo pill) + Bevacizumab in treatment of recurrent/progressive GBM & gliosarcoma patients (WHO grade IV malignant gliomas) (Bota)

**UCI 15-35**
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent GBM or Anaplastic Astrocytoma (Bota)

** opening soon



For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu 0218